Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome inpatients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial - Puig, N; Perez, JJ; Aires, I; Garcia-Sanz, R; Castro, S; Gonzalez-Calle, V; Gutierrez, NC; Mateos, MV; Agullo, C; Contreras, T; Calasanz, MJ; Rodriguez-Otero, P; et al. (HAEMATOLOGICA, 2024)